A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the safety of LY2409021 in healthy
participants and participants with diabetes. The study drug is given as single oral doses.
Each participant can receive up to 3 doses, with a minimum 7 day washout between dosing
periods. Side effects will be documented. This study is approximately 9 weeks long, not
including screening. Screening is required within 6 weeks prior to the start of the study.